GTx, Inc. Share Price Nasdaq
Equities
US40052B2079
Biotechnology & Medical Research
Sales 2024 * | 538K 42.92M | Sales 2025 * | 675K 53.9M | Capitalization | 24.54M 1.96B |
---|---|---|---|---|---|
Net income 2024 * | -37M -2.95B | Net income 2025 * | -48M -3.83B | EV / Sales 2024 * | 45.6 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 36.3 x |
P/E ratio 2024 * |
-0.78
x | P/E ratio 2025 * |
-0.98
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.25% |
Latest transcript on GTx, Inc.
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 31/12/96 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 31/03/17 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 16/05/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 31/12/96 |
Dan Kisner
BRD | Director/Board Member | 77 | 06/06/19 |
Rosemary Mazanet
BRD | Director/Board Member | 67 | 26/01/21 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |